Peptides DB
Research-centric peptide and protocol reference hub

IGF-1 DES (Des(1-3) IGF-1) record · updated 20h ago

Muscle & body compHealing & recoveryGrade A · human clinicalResearch use only
All 15 studiesJump to the evidenceCompare
What is IGF-1 DES (Des(1-3) IGF-1) used for?

IGF-1 DES (Des(1-3) IGF-1) is a truncated IGF-1 analog studied for localized muscle growth and tissue repair, with reduced IGFBP binding and higher local receptor activity.

How it works: IGF-1 receptor agonist

Primarily researched for · Muscle & body comp

Development stage

where IGF-1 DES (Des(1-3) IGF-1) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 62 registered trials. It describes the research record, not a recommendation.

Identity
NameIGF-1 DES (Des(1-3) IGF-1)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMuscle
Research levelModerate Research
Discovered byCurated master list · 2026
Pharmacology
MechanismIGF-1 receptor agonist
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 20, 2026. How this works →
Research stats
Total studies15
Human / animal / cellular10 / 1 / 2
Highest trial phasePhase 4
Years covered2013–2026
Latest study6d ago
Publication history
20132026
Research funding
1,320 NIH projects · $27.9M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

15 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Risk Factors for Peritonitis Associated With Endoscopic Ultrasound-guided Hepaticogastrostomy.
FindingBile duct diameter ≤3 mm had an odds ratio of 4.0 for peritonitis, p=0.039.
Human2026Full text read0.80
Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial.
FindingThe absolute difference in all-cause mortality between groups was -0.68% (95% CI -3.95 to 2.60).
Human2026Full text read0.90
Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies.
Finding39.5% ASAS40 response in r-axSpA filgotinib group vs 20.9% PBO, P=0.001, n=258.
Human2026Full text read0.90
Clinical Outcomes After Failed Endoscopic Detorsion for Sigmoid Volvulus: A Single-Center Retrospective Cohort Study.
FindingSuccessful detorsion achieved in 21 of 43 patients (48.8%).
Human2026Full text read0.80
Risk Stratification for Rebleeding in Obscure Gastrointestinal Bleeding After Comprehensive Gastrointestinal Evaluation.
FindingRebleeding rates were 5.6%, 17.5%, 27.3%, and 100% for scores 0, 1, 2, and 3, respectively.
Human2026Full text read0.80
Clinical Utility and Safety of a Novel Ultraslim Catheter-Type Peroral Cholangioscope/Pancreatoscope: A Single-Center Case Series.
FindingClinical success achieved in 11/12 cases (91.7%)
Human2026Full text read0.80
State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges.
Finding10.7 million people developed tuberculosis in 2024.
—2026Partial text0.50
Distinct molecular profiles characterize the spontaneous growth rate of IDHmt low-grade astrocytoma and oligodendroglioma, WHO grade 2
FindingMedian TVGR was 0.241 year -1 for codeleted LGG vs 0.424 year -1 for non-codeleted LGG, p<0.001.
Human2025Full text read0.80
Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
FindingGefitinib caused a 50% reduction in S-phase population.
In vitro2013Full text read0.80
Detection of LongR(3) -IGF-I, Des(1-3)-IGF-I, and R(3) -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes.
FindingDes(1-3)-IGF-I and R(3)-IGF-I detectable until 24 h after 100 μg/kg IM injection in rats.
Animal2021Full text read0.70
Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementias.
FindingTwofold increased risk of presenting with Braak neurofibrillary tangles stage of >4 in the tenth decile of the polygenic score compared to median score group.
review2025Full text read0.90
Multi-Omics Integration Reveals Incomplete Reactivation of Developmental Cell-Cycle Programs in Adult Human Infarcted Hearts.
Finding5% of cardiomyocytes re-enter the cell cycle after acute myocardial infarction.
Human2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching IGF-1 DES (Des(1-3) IGF-1) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much IGF-1 DES (Des(1-3) IGF-1) is discussed should be drawn from it.